LQDA today

$56.49+$1.28 (+2.32%)close Nov 12, 2026

Trend

DailyDowntrend (starting)

4 hourLeaning Bullish

1 hourLeaning Bearish

15 minStrong Bullish

5 minStrong Bearish

Daily trend turns up above $74.74

Key levels

Resistance$65.74

Resistance$59.75

Support$53.06

Support$47.20

About Liquidia

Liquidia is a biopharmaceutical company focused on treatments for respiratory and vascular conditions, including pulmonary arterial hypertension and pulmonary hypertension tied to interstitial lung disease. Its marketed therapy delivers treprostinil as a dry powder through an inhaler, and it also promotes a generic injectable treprostinil with Sandoz across the United States. The company is developing L606, an investigational liposomal treprostinil, and operates through its subsidiaries Liquidia Technologies and Liquidia PAH.

Based on the company's 10-K filed Mar 5, 2026.

Nasdaq · Healthcare

Liquidia Corp (LQDA)

$55.21+3.81 (+7.41%)

WATCHLISTGrade: B+Risk: MEDIUM

1D 5D1M1Y 5Y MaxSign up for all timeframes

High56.79

Low52.76

Open54.00

Volume3.67M

Avg Vol4.71M

VWAP54.74

30d High55.21

30d Low25.91

30d Chg+97.25%

See full chart with real-time data

What Is the Price Target for LQDA?

SEPT Low Target

$33.00

SEPT Mid Target

$77.00

SEPT High Target

$92.00

Analyst Consensus

$77.00

Current: $55.00Upside: +40.0%Confidence: 85%Method: Analyst Consensus

Is LQDA a Buy or Sell Right Now?

Investability Score

WATCHLIST12-18 months

News summary · last 30 days

Nov 10▲ UpEarningsUpgrade5 articles

Liquidia shares closed at $51.40, up 5.48% on volume of 2,370,324, after the drugmaker reported third-quarter 2026 adjusted earnings of $1.71 per share, well ahead of the $0.96 consensus, and revenue of $225 million versus the $214.182 million estimate. The strong beat, which excluded a litigation settlement from the adjusted figure, was discussed on the company's Q3 2026 earnings call and accompanied by a Form 8-K filing on the results. Separately, BTIG reiterated its Buy rating and lifted its price target to $87, reinforcing the bullish tone. The combination of a high-impact earnings beat and a low-impact analyst upgrade points to a positive direction for the stock.

Oct 14▲ UpLegalUpgrade3 articles

Liquidia shares closed down 4.93% at $33.94 despite a major legal catalyst, as the stock gave back early gains after spiking to a high of $38.64. The company announced a global settlement agreement with United Therapeutics, resolving all pending litigation and ensuring YUTREPIA remains available to PAH patients without disruption. Wells Fargo maintained an Equal-Weight rating while raising its price target to $33, suggesting limited upside from current levels. The pullback from intraday highs indicates profit-taking following the settlement news, though the resolution removes a significant overhang for the stock.

Critical news

Nov 10HIGHEarnings: growth/beat

Thesis

•Revenue growing 1031.2% YoY with ACCELERATING trend — accelerating momentum.

AI-Powered Trading Signals

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for LQDA.

Start Free Trial →

Is LQDA Overvalued or Undervalued?

Valuation Verdict

OVERVALUED

Methods Used

P/E Forward, P/B, Analyst Consensus

Fair Value

$58.14

Moat Score

NARROW

3/9

Piotroski Score

7.2

Altman Z-Score

What Is Smart Money Doing with LQDA?

Insider Signal

SELLING

0 buys / 9 sells (90d)

Congress Signal

NEUTRAL

0 buys / 0 sells (90d)

Institutional

N/A

Short Squeeze Risk

HIGH

Signal: HIGH_SHORT_INTEREST

Recent Insider Activity

Name	Title	Type	Shares	Value	Date
Adair Jason	officer	Sale	688	$30K	Oct 26, 2026
Boyle Dana	officer	Sale	1,581	$68K	Oct 26, 2026
Adair Jason	officer	Sale	7,301	$208K	Oct 12, 2026
Kaseta Michael	officer	Sale	18,938	$539K	Oct 12, 2026
JEFFS ROGER	director officer	Sale	32,744	$933K	Oct 12, 2026
Adair Jason	officer	Buy	3,906	-	Oct 9, 2026
Adair Jason	officer	Buy	2,474	-	Oct 9, 2026
Adair Jason	officer	Buy	3,868	-	Oct 9, 2026
Kaseta Michael	officer	Buy	5,828	-	Oct 9, 2026
Kaseta Michael	officer	Buy	7,049	-	Oct 9, 2026

Track Smart Money Across 4,000+ Stocks

Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.

See All Smart Money Signals →

LQDA Growth Story

Revenue YoY

1031.2%

3yr Revenue CAGR

115.0%

EPS Growth YoY

50.92%

FCF Growth YoY

59.3%

Revenue Trend

ACCELERATING

Dark Pool Trades for LQDA

PREVIEW

SEPT Investing tracks real-time dark pool institutional trades for LQDA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.

Time	Price	Size	Value	Side
14:36:47	$55.50	3,750	$$208K	SELL
14:36:47	$55.50	2,500	$$139K	SELL
14:36:47	$55.50	1,400	$$78K	SELL
14:34:25	$55.57	1,300	$$72K	SELL
14:34:25	$55.70	2,800	$$156K	MIDPOINT

5 dark pool trades shown · $$653K preview volume

Real-time institutional flow, block trades, and net positioning

See all dark pool activity

Options Flow for LQDA

PREVIEW

SEPT Investing provides real-time options flow tracking for LQDA, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.

Type	Strike	Expiry	DTE	Premium	Size	Trade
CALL	$57	Nov 13	1	$$40	1	SWEEP
CALL	$57	Nov 13	1	$$90	1	SWEEP

2 options trades shown · 100% calls

Unusual activity, GEX levels, max pain, and dealer positioning

See full options flow

Full AI Research Report

SEPT's Trading AI has generated a free, downloadable PDF research report for Liquidia Corp (LQDA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.

Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...

AI-Powered Trading Signals.

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.

Try SEPT Free for 7 Days →

LQDA — frequently asked questions

What is LQDA stock price today?

Liquidia Corp (LQDA) is at $56.49, up 2.32% (+$1.28) at the Nov 12, 2026 close.

Why is LQDA stock moving today?

Latest LQDA news — Nov 11, 2026: Raymond James keeps Liquidia buy rating, lifts target to $77 · Nov 11, 2026: BTIG Lifts Liquidia Target to $87

Why did LQDA stock move on Nov 10, 2026?

What is the LQDA price target?

The average analyst price target for LQDA is $77.00, ranging from $33 to $92, based on 9 analysts. Latest: Needham maintains on Nov 11, 2026.

What do analysts rate LQDA?

Analyst ratings for LQDA: 2 Buy, 19 Hold, 3 Sell — consensus Hold.

Did LQDA beat earnings?

LQDA last reported on Nov 10, 2026: EPS -$2.64 vs $0.94 expected — a miss of 380.9%.

What is LQDA's P/E ratio?

LQDA trades at a P/E of 39.4 vs a Healthcare average of 17.7.

Does LQDA pay a dividend?

LQDA does not currently pay a dividend.

What are LQDA support and resistance levels?

Support: $53.06, $47.20, $41.52. Resistance: $59.75, $65.74, $74.74.

What are insiders doing with LQDA?

Insider activity: SELLING, 0 buys and 9 sells in the last 90 days.

What is the latest news on LQDA?

Nov 11, 2026: Raymond James keeps Liquidia buy rating, lifts target to $77 · Nov 11, 2026: BTIG Lifts Liquidia Target to $87 · Nov 11, 2026: Needham keeps Buy rating on Liquidia, lifts price target